Phase 2 N=34 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Recurrent Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate Using Response Evaluation Criteria in Solid Tumors Version 1.1 — 2; 18; 14; 1 Participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Phase 2 N=39 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Phase 3 N=129 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Metastatic · Uveal Melanoma
Primary: Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival…
Phase 2 N=38 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Patients With Disease-free Survival (DFS) — 8 Participants
Phase 2 N=48 SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Stage IV Uveal Melanoma
Primary: Clinical Benefit Rate of Previously Treated and Naive Patients — 0; 0; 7; 6 Participants
Phase 1 N=10 Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Uveal Melanoma · Choroid Neoplasm
Primary: Occurrence of Adverse Events — 1; 3; 5; 0 Participants
Phase 2 N=23 Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
Phase 2 N=53 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Uveal Melanoma · Liver Metastases
Primary: Response of Liver Metastases — 0; 0; 5; 3 participants
Phase 2 N=54 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Metastatic Malignant Uveal Melanoma
Primary: Disease Control Rate — 18; 8 Participants
Phase 2 N=14 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Metastatic Malignant Neoplasm in the Liver · Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) — 0; 0; 8; 5 Participants
N/A N=1 Treatment With Intravitreal Avastin for Large Uveal Melanomas
Uveal Melanoma
Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants
Phase 2 N=57 Study in Subjects With Small Primary Choroidal Melanoma
Uveal Melanoma · Ocular Melanoma · Choroidal Melanoma
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] of Light-activated AU-011 — 3; 3; 3; 3 Participants
Phase 3 N=10 Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Choroidal Melanoma
Primary: Mean Tumor Thickness — 2.91 mm
Phase 2 N=8 Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Choroidal Melanoma
Primary: To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal…
Phase 2 N=378 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Uveal Melanoma
Primary: Efficacy: Overall Survival — 21.7; 16.0 Months — p=<0.0001
Phase 2 N=27 Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma
Primary: Objective Response Rate (ORR) — 7.7 percentage of participants
Phase 2 N=16 Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Uveal Melanoma With Liver Metastases
Primary: Objective Response Rate (ORR) — 3 Participants
Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Phase 2 N=41 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Objective Response Rate (CR + PR) — 7.5 percentage of participants
Phase 2 N=170 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants
Phase 2 N=14 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Uveal Melanoma
Primary: Number of Participants With Complete Response (CR) — 13; 0 Participants
Phase 2 N=146 A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Uveal Melanoma
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) in Phase 1 — 0; 1; 2; 0 Participants
Phase 2 N=4 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
Intraocular Melanoma
Primary: Overall Response Rate — 0 patients
Phase 2 N=18 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Participants With Response — 0; 0; 8; 9 participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=17 STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Ocular Melanoma
Primary: 4-month Progression Free Survival (PFS) Rate — 0.059; 0.118 proportion of participants
Phase 2 N=24 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Acral Lentiginous Malignant Melanoma · Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size
Primary: Objective Tumor Response (Partial or Complete Response) According to RECIST — 0 participants